Seelos Therapeutics
New York, US · Nevada corporation · 1 known investors
Biotech
Founders & leadership
RM
Raj MehraChief Executive Officer
MG
Michael GolembiewskiChief Financial Officer
BD
BRIAN DORSEYExecutive
CB
CATHERINE BOVENIZERExecutive
NM
NEIL MORTONExecutive
Board
BL
Brian LianBoard director
MD
Margaret DalesandroBoard director
RW
Richard W. PascoeBoard director
RR
RUSTY RAYBoard director
WW
WENDELL WIERENGABoard director
SD
SANDFORD D. SMITHBoard director
KG
KLEANTHIS G. XANTHOPOULOSBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.3M disclosed across 2 of 7 rounds · 2016–2024
▶$1.1MofferedJul 2024 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MofferedJul 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raj MehraExecutive Officer
- Brian LianDirector
- Margaret DalesandroDirector
- Michael GolembiewskiExecutive Officer
- Richard W. PascoeDirector
- Offering amount
- $1.1M
- Sales commissions
- $48.7K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2MofferedMay 2024 · 2 investors · BiotechnologyRule 506(b)
▶$2MofferedMay 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GolembiewskiExecutive Officer
- Raj MehraExecutive Officer, Director
- Margaret DalesandroDirector
- Brian LianDirector
- Richard W. PascoeDirector
- Offering amount
- $2M
- Sales commissions
- $79.6K
- Finders' fees
- $50K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.6MofferedFeb 2024 · 3 investors · BiotechnologyRule 506(b)
▶$3.6MofferedFeb 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Margaret DalesandroDirector
- Brian LianDirector
- Daniel J. O'ConnorDirector
- Michael GolembiewskiExecutive Officer
- Raj MehraExecutive Officer, Director
- Richard W. PascoeDirector
- Offering amount
- $3.6M
- Sales commissions
- $280K
- Finders' fees
- $65K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Jan 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$5.6MofferedSep 2020 · 13 investors · BiotechnologyRule 506(b)
▶$5.6MofferedSep 2020 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Judith DunnDirector
- Daniel J. O'ConnorDirector
- Richard W. PascoeDirector
- Brian LianDirector
- Raj MehraExecutive Officer, Director
- Offering amount
- $5.6M
- Sales commissions
- $490.2K
- Finders' fees
- $80K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Sep 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4MofferedAug 2019 · 9 investors · BiotechnologyRule 506(b)
▶$4MofferedAug 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raj MehraExecutive Officer, Director
- Brian LianDirector
- Richard W. PascoeDirector
- Robin L. SmithDirector
- Daniel J. O'ConnorDirector
- Offering amount
- $4M
- Sales commissions
- $469.9K
- Finders' fees
- $80K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.7MraisedSep 2017 · 9 investors · PharmaceuticalsRule 506(c)
▶$3.7MraisedSep 2017 · 9 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- WENDELL WIERENGADirector
- SANDFORD D. SMITHDirector
- NEIL MORTONExecutive Officer
- RUSTY RAYDirector
- BRIAN DORSEYExecutive Officer
- PAUL V. MAIERDirector
- KLEANTHIS G. XANTHOPOULOSDirector
- RICHARD W. PASCOEExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- Sales commissions
- $258.4K
- Placement agents
- H.C. WAINWRIGHT & CO., LLC
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
▶$3.7MraisedOct 2016 · 2 investors · PharmaceuticalsRule 506(c)
▶$3.7MraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- BRIAN DORSEYExecutive Officer
- RUSTY RAYDirector
- CATHERINE BOVENIZERExecutive Officer
- WENDELL WIERENGADirector
- SANDFORD D. SMITHDirector
- KLEANTHIS G. XANTHOPOULOSDirector
- NEIL MORTONExecutive Officer
- RICHARD W. PASCOEExecutive Officer, Director
- PAUL V. MAIERDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- Sales commissions
- $327.5K
- Placement agents
- RODMAN & RENSHAW LLC
- First sale
- Sep 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapApplied Therapeutics10 shared keywordsApplied Therapeutics is a biopharmaceutical company developing treatments for rare diseases, with a portfolio focused on Classical Galactosemia and CMT-SORD. Its lead investigational drug, govorestat, targets disease pathways such as galactitol and sorbitol reduction.
Elicio10 shared keywordsElicio develops cancer immunotherapies including vaccines, immunomodulators, and adjuvants built on its lymph node-targeted AMP platform to activate and amplify cancer-fighting T cells. The company focuses on treating solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC).
Xilio Therapeutics9 shared keywordsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Exelixis8 shared keywordsExelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
Robinhood8 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Solu7 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Seelos Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- Who founded Seelos Therapeutics?
- Seelos Therapeutics was founded by Raj Mehra.
- Who are Seelos Therapeutics's investors?
- Seelos Therapeutics's investors include Altium Capital.
- How much funding has Seelos Therapeutics raised?
- Seelos Therapeutics has disclosed $7.3M raised across 2 of its 7 known rounds.
- Where is Seelos Therapeutics headquartered?
- Seelos Therapeutics is headquartered in New York, US.